查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1827434

按藥物類別、給藥途徑、分子類型、適應症、最終用戶和分銷管道分類的腫瘤藥物市場 - 全球預測 2025-2032

Oncology Drugs Market by Drug Class, Route of Administration, Molecule Type, Indication, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，抗癌藥物市場規模將成長至 3,864.1 億美元，複合年成長率為 7.92%。

主要市場統計數據
基準年2024年 2100億美元
預計2025年 2255.4億美元
預測年份：2032年 3864.1億美元
複合年成長率（%） 7.92%

對不斷發展的癌症治療領域進行簡潔、基礎性的定位，整合科學創新、交付方式以及對相關人員策略的影響

腫瘤學領域正處於曲折點，這得益於臨床進展、醫療服務提供方式的轉變以及供應鏈敏感性的提高。本介紹概述了推動開發商、投資者、臨床醫生和付款人決策的關鍵力量，為策略行動定下了基調。近年來，治療方法創新已經超越了傳統的細胞毒性藥物，包括荷爾蒙療法、不斷擴大的免疫療法和高選擇性標靶藥物。在化療中，甲醇烷基化化合物和抗代謝物等藥物仍然是許多方案的基石。在免疫療法中，工程細胞平台正在擴展，包括 CAR T 細胞療法和基於查核點阻斷的全身免疫調節劑，例如 CTLA-4 和 PD-1/PD-L1。標靶治療不斷發展，包括單株抗體（包括嵌合體和人源化抗體）以及針對激酶和細胞週期調節劑的小分子抑制劑。

同時，對給藥方式和給藥方式的考量已成為策略差異化因素。靜脈、皮下和肌肉注射劑與日益擴展的口服方案共存，優先考慮門診患者的便利性。包括單株抗體和治療性疫苗在內的生物製藥的興起伴隨著強調生物有效性和細胞內靶向的小分子藥物項目。適應症很複雜，從白血病和淋巴瘤等血液系統骨髓惡性腫瘤，到急性骨髓性白血病和慢性淋巴性白血病、何傑金氏病金癌和非何傑金氏病癌等亞型，以及乳癌、大腸直腸癌、肺癌和攝護腺癌等固體癌腫瘤。最終用戶包括醫院、專科診所和研究機構，每個機構都需要獨特的供應、報銷和臨床整合策略，通路涵蓋醫院藥房、零售店和線上管道，影響藥物的可及性和依從性。

本概述強調，成功的腫瘤學策略必須將科學創新與生產、監管參與和商業營運的實際規劃相結合。以下章節將探討轉型變革、關稅相關壓力、基於細分市場的優先事項、區域差異化因素、競爭行動，以及領導者在日益複雜的治療和商業說明中應對的實用建議。

評估推動下一代癌症治療和護理模式的關鍵技術、監管和商業性轉變

過去十年，癌症領域發生了翻天覆地的變化，重新定義了治療標準、商業模式和投資重點。隨著嵌合抗原受體T細胞療法的成熟以及針對CTLA-4和PD-1/PD-L1路徑的查核點抑制劑的擴展，免疫腫瘤學的快速發展改變了治療模式。這些治療方法不僅在先前難以治癒的疾病中取得了持久的療效，也重塑了人們對長期疾病控制和合併用藥策略的預期。同時，標靶治療的開發也在加速，單株抗體（包括嵌合體和人源化抗體）與小分子抑制劑（例如蛋白酪氨酸激酶抑制劑和週期蛋白依賴型激酶抑制劑）相輔相成，因此能夠精準標靶化致癌因子。

生技藥品生產和複雜細胞療法的供應鏈正在經歷與臨床進展同步的開發創新，包括複雜的低溫運輸物流、與專業合約開發和受託製造廠商的合作，以及對某些極具挑戰性療法的現場能力的需求。同時，隨著醫療保健系統和患者尋求減輕醫療機構負擔並提高依從性的門診替代方案，口服給藥正日益受到青睞。數位化療法、遠端監控和分散式臨床試驗模式使更廣泛的患者參與和更快的數據收整合為可能，而真實世界證據計畫也日益支持報銷方案。

監管途徑正在透過加速核准機制、增加對替代終點和核准後承諾的依賴來適應新興科學。在商業性，付款方正在嘗試基於結果和價值的基本契約，而製造商則面臨著將定價與已證實的臨床效用掛鉤的壓力。總而言之，這些轉變迫使相關人員追求靈活的開發平台、有韌性的生產佈局和全面的證據策略，以充分了解新興腫瘤藥物資產的治療和經濟價值。

到 2025 年的累積關稅趨勢及其與供應鏈、籌資策略和腫瘤學相關人員之間的獲取動態的相互作用的綜合分析

改變跨境貿易和關稅的政策行動將對複雜的醫藥供應鏈產生重大影響，而2025年宣布或實施的關稅變化的累積影響需要謹慎解讀。關稅壓力可能表現為原料藥、生技藥品（例如一次性組件和細胞培養基）以及特種輔料的投入成本上升。為此，製造商可能會重新評估其供應商組合，並加快替代供應商和委託製造製造商的資格認證，以降低集中風險。因此，一些公司可能會採取部分在岸或近岸外包策略，以緩解關稅引發的波動，但這些措施會帶來資本和時間成本、監管重新認證要求以及潛在的產能限制。

面對採購成本的上升，醫院、專科診所和醫院藥局可以加強處方箋管理，優先選擇具有明確治療價值和採購彈性的藥品。研究機構可能會因承擔與關稅相關的採購和營運成本上漲而出現預算錯位，這可能會影響研究者主導研究的速度和範圍。分銷管道（包括線上藥局和零售藥局）可以透過重新協商供應商合約和調整庫存策略來適應變化，以在保護淨利率的同時維持患者可及性。

在研發方面，上游成本的上升可能會對研發預算造成壓力，並可能改變那些治療差異較小的後期研發產品的核准/未核准標準。同時，隨著企業改變生產佈局，監管機構可能會嚴格審查供應的連續性和品質保證。因此，相關人員應追求全面的供應鏈可視性、關稅衝擊情境規劃，並積極主動地與供應商和監管機構溝通，以在不損害創新獎勵的情況下，維持藥物的可及性和臨床的連續性。

詳細的細分情報將治療層級、給藥方法、分子類型、臨床適應症和管道行為與戰略要務聯繫起來

以細分市場主導的觀點揭示了跨治療層級、給藥途徑、分子類型、適應症、最終用戶和分銷管道的差異化商業機會和營運需求。按藥物類別細分，雖然傳統化療在組合方案中仍然必不可少，烷化劑和抗代謝藥物在某些方案中有用，但免疫療法子類別（CAR-T 細胞療法和查核點抑製劑）由於其個性化生產和長期療效特徵而具有獨特的製造、臨床和商業性方法。查核點抑制劑的子集，包括 CTLA-4 抑制劑和 PD-1/PD-L1 抑制劑，強調全身性免疫調節，並需要與持久反應指標相關的獨特證據。同時，週期蛋白依賴型激酶抑制劑和蛋白酪氨酸激酶抑制劑等小分子類別具有獨特的開發和交付優勢。

靜脈、皮下或肌肉注射療法需要輸液能力、訓練有素的臨床工作人員和強大的低溫運輸管理，而口服製劑則允許分散配藥和依從性解決方案。考慮到分子類型，市場分為生技藥品（如單株抗體和疫苗）和小分子，每種製劑都需要量身定做的製造生態系統和監管證據包。基於適應症的細分突出表明，白血病和淋巴瘤等骨髓惡性腫瘤（包括急性骨髓性白血病、慢性淋巴性白血病、何傑金氏淋巴瘤和非何傑金氏淋巴瘤等亞型）正在推動對細胞療法和新型組合策略的重點需求，而乳癌、結直腸癌、肺癌和前列腺癌等固體癌正在推動廣泛的人群水平篩檢、生物標記開發和長期生存護理的考慮。終端使用者細分凸顯了醫院、研究機構和專科診所之間不同的採購和採用動態。最後，分銷管道（醫院、線上和零售）的差異決定了治療藥物的庫存、報銷和獲取方式，直接影響依從性和後續療效。整合這些細分層面，有助於根據臨床和商業實際情況，制定有針對性的產品組合優先排序、供應鏈設計和證據產生活動。

地理差異和可操作的區域情報，使監管現實、製造能力和付款人環境與准入策略保持一致

區域動態顯著影響全球腫瘤生態系的發展重點、報銷途徑和可及性策略。在美洲，先進的臨床基礎設施、深入的付款人和商業性參與以及專注的生物製藥投資正在推動高成本創新治療方法的快速應用，特別是在骨髓惡性腫瘤和精準靶向適應症領域。該地區的監管和報銷討論越來越依賴現實世界的結果和基於價值的安排，這些影響著產品上市順序和商業性准入計劃。歐洲、中東和非洲的法規環境和付款人能力各不相同，因此打入市場策略也各不相同。雖然西方醫療保健系統通常強調衛生技術評估主導的評估和價格談判，但中東和非洲地區面臨基礎設施和產能限制，這會影響複雜生技藥品和細胞療法的推出時間表。因此，製造商必須客製化准入模式、本地夥伴關係和能力建設舉措，以解決特定國家/地區的報銷和交付限制。亞太地區是一個充滿活力的市場，擁有強大的生產能力、快速成長的臨床試驗數量以及不斷發展的報銷制度。該地區多個國家正在投資國內生技藥品和小分子藥物的生產，這為全球研發機構帶來了競爭壓力和合作機會。在所有地區，在地化的臨床證據、與本地意見領袖的合作以及強大的供應鏈韌性對於持續推進產品上市和擴大患者可及性都至關重要，每個地區都需要製定符合其醫療保健體系架構和患者群體需求的客製化監管和商業策略。

決定腫瘤學競爭優勢的關鍵生物製藥、生物技術和製造合作夥伴的策略行動和能力發展

腫瘤學公司的行為反映了其對科學機會和營運複雜性的廣泛策略頻譜。大型綜合製藥公司優先考慮產品組合多元化，在創新生物製藥和細胞療法與小專利權系列的逐步改進之間取得平衡，同時利用規模效應投資於生產能力和全球商業網路。開發型生技公司通常專注於作用機制和基於生物標記的患者選擇驅動差異化的適應症，而開發細胞療法的公司則專注於建立專業化生產能力和夥伴關係，以實現分散式交付。合約開發和受託製造公司正在擴展其能力，以應對生物製藥和複雜的細胞療法工作流程，使其成為尋求降低資本強度和加速產能推出的贊助商的重要合作夥伴。

這些公司類型的通用策略行動包括尋求策略聯盟、授權合約和選擇性併購，以填補能力差距，特別是在基因編輯、細胞治療自動化和高級分析等領域。該公司還在投資證據生成平台，將臨床試驗數據與真實世界治療結果相結合，以支持付款人談判和基於價值的合約。在營運方面，公司正在增強供應鏈視覺性和雙重採購策略，以減少受關稅主導的成本波動影響，並確保溫度敏感型生技藥品的連續性。競爭差異化越來越依賴於展示長期臨床效用、管理複雜物流以及提供符合不同付款人需求的可靠定價和存取計劃的能力。

為高階主管提供實用的優先建議，以增強其腫瘤學產品組合的供應連續性、證據產生和商業性準備

行業領導者必須採取一系列協同行動，將科學進步轉化為永續的商業性和臨床影響。首先，透過多方採購、庫存最佳化和在可行的情況下策略性地在岸外包，優先考慮供應鏈的彈性，這可以減輕關稅引發的成本衝擊，並確保溫敏性生技藥品和細胞治療產品的穩定性。其次，在開發早期納入真實世界證據策略和健康經濟終點，可以使臨床開發與付款人證據預期一致，從而提高報銷準備度並減少上市摩擦。第三，投資製造夥伴關係和模組化生產技術，特別是針對複雜生技藥品和CAR-T平台，可加速規模化生產，同時控制資本支出。

第四，設計靈活的商業化模式，既能適應醫院管理，又能適應門診口服治療，可以改善病患的用藥管道，促進護理過渡。第五，建立結合診斷和治療能力的策略聯盟，可以加強生物標記主導的定位，實現有針對性的適應症。第六，採用數位化和分散式臨床試驗方法可以擴大患者招募，加快數據收集，並支持核准後證據的產生。第七，與付款人協商創新的合約安排，包括基本契約結果的契約，可以使價格與臨床表現保持一致，並降低採用高成本療法的風險。最後，促進研發、監管事務、製造和商業團隊之間的跨職能合作，可以確保更快的決策週期和一致的打入市場策略。總之，這些建議為尋求保持創新同時克服成本壓力和准入障礙的組織提供了切實可行的藍圖。

結合相關人員訪談、文獻綜合和數據三角測量的透明、多方法研究途徑檢驗了腫瘤學的見解和假設

本研究整合了一手和二手研究，旨在提供嚴謹且檢驗的見解。一手研究包括對各種相關人員進行結構化訪談，包括臨床研究人員、醫院藥劑師、相關人員、專科診所主任以及生物製藥公司和製造外包的高階主管。進行這些訪談是為了從多個觀點了解實務、採購行為和證據期望。二手研究包括對同行評審文獻、監管指導文件、公開意見書、會議記錄和技術白皮書的系統性回顧，以建立全面的依證。使用數據三角測量技術來協調不同資訊來源的見解，並在後續專家諮詢中對研究結果進行交叉檢驗，以確保一致性並解決任何差異。

應用分段映射將治療層級、給藥途徑、分子類型、適應症、最終用戶和分銷管道與觀察到的採用模式和操作限制進行匹配。品質保證步驟包括方法同儕審查、來源可追溯性和敏感度分析，以確定高度不確定性的領域。這種方法有其限制：相關人員訪談反映的是當前的做法和看法，這些做法和看法可能會迅速變化，公共文獻可能落後於快速發展的技術創新。為了解決這些局限性，本研究強調透明的假設和對關鍵結論的具體證據的引用，並鼓勵用戶透過與策略問題一致的有針對性的主要參與來補充這項工作。所有關鍵互動都適用道德標準和保密通訊協定，參與者共用的專有資訊按照商定的保密條款處理。

結論性綜合強調了技術創新、營運準備和政策考慮的融合，這些將決定腫瘤學的長期影響

本文展現的科學創新、營運複雜性和政策動態的融合，凸顯了腫瘤學相關人員必須既敏捷又謹慎。免疫療法和標靶藥物的進展展現出臨床前景，但要實現規模化應用，需要製定涵蓋生產彈性、證據生成和自適應商業化的整合策略。到2025年，關稅和貿易發展將增加營運風險，這可能會影響投入成本、採購行為和取得途徑，因此，供應鏈可視性和情境規劃至關重要。

市場區隔和區域分析表明，治療方法、交付和地理差異需要量身定做的方法，而不是一刀切的方案。投資於模組化製造、智慧夥伴關係和早期付款人參與的公司將更有能力應對報銷的複雜性，並確保創新治療方法的持久應用。同時，醫療系統和付款人將受益於更清晰的療效數據和將成本與長期患者利益相結合的協作模式。最後，目前的環境有利於那些將科學嚴謹性與營運遠見結合的組織。相關人員將最有能力將治療方法突破轉化為持續的臨床和商業性成功。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 快速實施針對固體癌特異性突變的個人化新抗原疫苗平台
  • 提高超靈敏液態生物檢體檢測的整合度，用於監測造血系統惡性腫瘤的微量殘存疾病
  • 將靶向 CD19 的 CAR-T 細胞療法擴展至瀰漫大 B 細胞淋巴瘤的初始治療通訊協定
  • 新一代 KRAS G12C 和 G12D 抑制劑的出現，在肺癌和大腸直腸癌中表現出持久療效
  • 製藥公司與診斷開發商擴大PD-L1伴隨診斷聯合開發案的合作

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章：按藥物類別分類的抗癌藥物市場

  • 化療藥物
    • 烷化劑
    • 抗代謝物
  • 荷爾蒙療法劑
  • 免疫治療藥物
    • CAR-T細胞療法
    • 查核點抑制劑
      • CTLA-4抑制劑
      • PD-1/PD-L1抑制劑
  • 標靶治療藥物
    • 單株抗體
      • 嵌合體
      • 人性化
    • 小分子抑制劑
      • 週期蛋白依賴型激酶抑制劑
      • 蛋白酪氨酸激酶抑制劑

第9章 抗癌藥物市場（依給藥途徑）

  • 注射
    • 肌肉注射
    • 靜脈
    • 皮下
  • 口服

第 10 章 抗癌藥物市場（依分子類型）

  • 生物製藥
    • 單株抗體
    • 疫苗
  • 小分子

第11章 癌症藥物市場（按適應症）

  • 血癌
    • 白血病
      • 急性骨髓性白血病
      • 慢性淋巴性白血病
    • 淋巴瘤
      • 何傑金氏淋巴瘤
      • 非何傑金氏淋巴瘤
  • 乳癌
  • 大腸直腸癌
  • 肺癌
  • 攝護腺癌

第12章 抗癌藥物市場（依最終用戶）

  • 醫院
  • 研究所
  • 專科診所

第13章 抗癌藥物市場（依通路）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

第14章 抗癌藥物市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 抗癌藥物市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國抗癌藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • AbbVie Inc.
    • Agenus Inc.
    • Amgen Inc.
    • Apres-demain SA
    • Aspen Pharmacare Holdings Limited
    • Astellas Pharma Inc.
    • AstraZeneca PLC
    • Bayer AG
    • BeiGene, Inc.
    • Bristol-Myers Squibb Company
    • CH Boehringer Sohn AG & Co. KG
    • Cipla Limited
    • Eli Lilly and Company
    • GSK plc
    • Johnson & Johnson Services, Inc.
    • Merck KGaA
    • Pfizer Inc.
    • Puma Biotechnology, Inc.
    • Roche Holding AG
    • Shorla Oncology
    • Sun Pharmaceutical Industries Ltd
    • Sutro Biopharma, Inc.
    • Takeda Pharmaceutical Company Limited
    • Viatris Inc.
Product Code: MRR-434CCDA05255

The Oncology Drugs Market is projected to grow by USD 386.41 billion at a CAGR of 7.92% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 210.00 billion
Estimated Year [2025] USD 225.54 billion
Forecast Year [2032] USD 386.41 billion
CAGR (%) 7.92%

Concise foundational orientation to the evolving oncology therapeutic arena integrating scientific innovation, delivery modalities, and stakeholder implications for strategy

The oncology therapeutic landscape is at an inflection point shaped by converging clinical advances, shifting care delivery, and heightened supply chain sensitivity. This introduction frames the critical forces driving decision-making for developers, investors, clinicians, and payers, and sets the tone for strategic action. Over recent years, therapeutic innovation has broadened beyond traditional cytotoxic agents into a heterogeneous set of approaches that include hormonal therapies, an expanding immunotherapy universe, and highly selective targeted agents. Within chemotherapy, agents such as alkylating compounds and antimetabolites remain foundational for numerous regimens, while immunotherapy now spans engineered cellular platforms through CAR T-cell products and systemic immune modulators via checkpoint blockade, including CTLA-4 and PD-1/PD-L1 mechanisms. Targeted therapies continue to evolve across monoclonal antibody formats-both chimeric and humanized-and small molecule inhibitors targeting kinases and cell-cycle regulators.

In parallel, modality and delivery considerations have become strategic differentiators: injectable administrations delivered intravenously, subcutaneously, or intramuscularly coexist with expanding oral regimens that prioritize outpatient convenience. The rise of biologics, including monoclonal antibodies and therapeutic vaccines, sits alongside small-molecule programs that emphasize oral bioavailability and intracellular targets. Indication complexity ranges from hematologic malignancies such as leukemia and lymphoma, with further subtypes including acute myeloid leukemia and chronic lymphocytic leukemia and Hodgkin and non-Hodgkin categories, to solid tumor priorities like breast, colorectal, lung, and prostate cancers. End-user dynamics involve hospitals, specialty clinics, and research institutes that each demand distinct supply, reimbursement, and clinical integration strategies, while distribution routes span hospital pharmacies, retail and online channels that influence access and adherence.

This overview underscores that successful oncology strategies must integrate scientific innovation with pragmatic planning across manufacturing, regulatory engagement, and commercial operations. The sections that follow unpack transformative shifts, tariff-related pressures, segmentation-driven priorities, regional differentiators, competitive behaviors, and actionable recommendations designed to equip leaders to navigate an increasingly complex therapeutic and commercial environment.

Assessment of the major technological, regulatory, and commercial shifts that are driving the next generation of oncology therapies and care delivery models

The last decade has seen transformative shifts that are redefining standards of care, commercial models, and investment priorities across oncology. Rapid advances in immuno-oncology have altered treatment paradigms, driven by the maturation of CAR T-cell therapies and the expansion of checkpoint inhibitors targeting CTLA-4 and PD-1/PD-L1 pathways. These modalities have not only delivered durable responses in previously refractory indications but have also reshaped expectations for long-term disease control and combination strategies. Concurrently, targeted therapy development has accelerated, with monoclonal antibodies-both chimeric and humanized-being complemented by small molecule inhibitors such as tyrosine kinase inhibitors and cyclin-dependent kinase inhibitors that enable precision targeting of oncogenic drivers.

Manufacturing innovation has followed clinical progress, with biologics production and complex cell therapy supply chains necessitating advanced cold-chain logistics, specialized contract development and manufacturing organization partnerships, and on-site capabilities for some high-touch therapies. At the same time, oral administration has gained prominence as health systems and patients seek outpatient alternatives that reduce facility burden and improve adherence. Digital therapeutics, remote monitoring, and decentralized trial models are enabling broader patient engagement and faster data capture while real-world evidence programs increasingly support reimbursement narratives.

Regulatory pathways have adapted to novel science through expedited approval mechanisms and greater reliance on surrogate endpoints and post-approval commitments, which encourages earlier commercialization but also demands robust post-market evidence generation. Commercially, payers are experimenting with outcomes-based agreements and value-based contracting, forcing manufacturers to align pricing with demonstrable clinical benefit. Altogether, these shifts compel stakeholders to pursue flexible development platforms, resilient production footprints, and integrated evidence strategies to capture the full therapeutic and economic value of emerging oncology assets.

Integrated analysis of how cumulative tariff developments through 2025 interact with supply chains, procurement strategies, and access dynamics across oncology stakeholders

Policy actions that alter cross-border trade and tariffs have material implications for complex pharmaceutical supply chains, and the cumulative effects of tariff changes announced or implemented through 2025 require careful interpretation. Tariff pressure can manifest as higher input costs for active pharmaceutical ingredients, biologics raw materials such as single-use components and cell culture media, and specialty excipients. In response, manufacturers may re-evaluate supplier portfolios and accelerate qualification of alternate vendors or contract manufacturers to mitigate concentrated exposure. Consequently, some organizations will pursue partial onshoring or nearshoring strategies to reduce tariff-induced volatility, but those moves carry capital and time costs, regulatory requalification requirements, and potential capacity constraints.

Hospitals, specialty clinics, and hospital pharmacies facing increased procurement costs may implement tighter formulary management and prioritize medications with clearer therapeutic value and procurement flexibility. Research institutes may experience budgetary displacement as procurement and operational expenses absorb tariff-related increases, potentially influencing the pace and scope of investigator-initiated studies. Distribution channels, including online and retail pharmacies, may adapt by renegotiating supplier agreements or shifting inventory strategies to maintain patient access while protecting margins.

From a development perspective, increased upstream costs can pressure R&D budgets and may change go/no-go calculus for late-stage assets with marginal therapeutic differentiation. Meanwhile, regulatory authorities are likely to scrutinize supply continuity and quality assurance as companies modify manufacturing footprints. Stakeholders should therefore pursue comprehensive supply chain visibility, scenario planning for tariff shocks, and proactive engagement with suppliers and regulators to preserve access and clinical continuity without undermining innovation incentives.

In-depth segmentation intelligence linking therapeutic classes, administration modes, molecule types, clinical indications, and channel behaviors to strategic imperatives

A segmentation-driven perspective reveals differentiated opportunities and operational imperatives across therapeutic classes, administration routes, molecule types, indications, end users, and distribution channels. Drug class segmentation underscores that traditional chemotherapy remains essential in combination regimens, with alkylating agents and antimetabolites retaining utility for certain protocols, whereas immunotherapy's subsegments-CAR T-cell therapies and checkpoint inhibitors-drive distinct manufacturing, clinical, and commercial approaches due to their personalized production and long-term efficacy profiles. The checkpoint inhibitor subset, including CTLA-4 and PD-1/PD-L1 inhibitors, emphasizes systemic immune modulation and generates unique evidence needs tied to durable response metrics. Targeted therapies bifurcate into monoclonal antibodies and small molecule inhibitors; within monoclonal antibodies, differences between chimeric and humanized formats influence immunogenicity risk profiles and manufacturing complexity, while small molecule categories such as cyclin-dependent kinase inhibitors and tyrosine kinase inhibitors carry different development and delivery advantages.

Route of administration segmentation differentiates market access and patient experience: injectable therapies delivered intravenously, subcutaneously, or intramuscularly demand infusion capacity, trained clinical staff, and robust cold-chain management, while oral formulations enable decentralized dispensing and adherence solutions. Molecule type considerations separate biologics, including monoclonal antibodies and vaccines, from small molecules, each requiring tailored manufacturing ecosystems and regulatory evidence packages. Indication-based segmentation highlights that hematologic malignancies like leukemia and lymphoma, with subtypes such as acute myeloid leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma, create concentrated needs for cellular therapies and novel combination strategies, while solid tumors such as breast, colorectal, lung, and prostate cancers drive broad population-level considerations for screening, biomarker development, and long-term survivorship care. End-user segmentation emphasizes differentiated procurement and adoption dynamics across hospitals, research institutes, and specialty clinics. Finally, distribution channel distinctions among hospital pharmacies, online pharmacies, and retail pharmacies determine how therapies are stocked, reimbursed, and accessed, directly impacting adherence and downstream outcomes. Synthesizing these segmentation layers supports targeted portfolio prioritization, supply chain design, and evidence generation activities that align with clinical and commercial realities.

Geographic differentiation and actionable regional intelligence that align regulatory realities, manufacturing capacity, and payer environments to access strategies

Regional dynamics profoundly shape development priorities, reimbursement pathways, and access strategies across the global oncology ecosystem. In the Americas, a combination of advanced clinical infrastructure, deep payer-commercial engagement, and concentrated biopharmaceutical investment fosters rapid uptake of high-cost innovative therapies, especially in hematologic malignancies and precision-targeted indications. Regulatory and reimbursement discussions in this region increasingly hinge on real-world outcomes and value-based arrangements that influence launch sequencing and commercial access plans. Europe, Middle East & Africa feature varied regulatory environments and diverse payer capacities, prompting differentiated market entry strategies. Western European health systems often emphasize health technology assessment-driven evaluations and pricing negotiations, while regional pockets in the Middle East and Africa confront infrastructure and capacity limitations that affect adoption timelines for complex biologics and cell therapies. Manufacturers must therefore tailor access models, local partnerships, and capacity-building initiatives that address country-specific reimbursement and delivery constraints. Asia-Pacific encompasses highly dynamic markets with substantial manufacturing capacity, a rapidly growing clinical trial footprint, and evolving reimbursement landscapes. Several countries in this region are investing in domestic biologics and small-molecule production, which creates both competitive pressures and partnership opportunities for global developers. Across all regions, localization of clinical evidence, engagement with regional opinion leaders, and supply chain resiliency are critical for sustaining launches and scaling patient access, with each geography demanding bespoke regulatory and commercial strategies that reflect its health system architecture and patient population needs.

Strategic behaviors and capability development among leading biopharma, biotech, and manufacturing partners that define competitive advantage in oncology

Company behavior in oncology reflects a broad spectrum of strategic responses to scientific opportunity and operational complexity. Large integrated pharmaceutical organizations are prioritizing portfolio diversification that balances innovative biologics and cell therapies with incremental improvements in small molecule franchises, leveraging scale to invest in manufacturing capacity and global commercial networks. Emerging biotechs often pursue focused indications where mechanism-of-action clarity and biomarker-driven patient selection can drive differentiation, while companies developing cell therapies concentrate on building specialized manufacturing capabilities and partnerships for decentralized delivery. Contract development and manufacturing organizations are expanding capabilities for both biologics and complex cell therapy workflows, positioning themselves as essential partners for sponsors seeking to mitigate capital intensity and accelerate capacity ramp-up.

Across these company types, common strategic behaviors include pursuing strategic alliances, licensing arrangements, and selective M&A to fill capability gaps-particularly in areas such as gene editing, cell therapy automation, and advanced analytics. Firms are also investing in evidence-generation platforms that integrate clinical trial data with real-world outcomes to support payer negotiations and value-based contracting. Operationally, companies are strengthening supply chain visibility and dual-source strategies to reduce exposure to tariff-driven cost volatility and to ensure continuity for temperature-sensitive biologics. Competitive differentiation increasingly depends on the ability to demonstrate long-term clinical benefit, manage complex logistics, and present credible pricing and access plans aligned to diverse payer requirements.

Pragmatic and prioritized recommendations for executives to strengthen supply continuity, evidence generation, and commercial readiness for oncology portfolios

Industry leaders must execute a set of coordinated actions to convert scientific progress into sustainable commercial and clinical impact. First, prioritizing supply chain resilience through multi-sourcing, inventory optimization, and strategic onshoring where feasible will mitigate exposure to tariff-driven cost shocks and ensure stability for temperature-sensitive biologics and cell therapies. Second, aligning clinical development with payer evidence expectations by embedding real-world evidence strategies and health economics endpoints early in development will enhance reimbursement readiness and reduce launch friction. Third, investing in manufacturing partnerships and modular production technologies-particularly for complex biologics and CAR T platforms-can accelerate scale-up while managing capital outlay.

Fourth, designing flexible commercialization models that accommodate both hospital-administered and outpatient oral therapies will improve patient access and facilitate care transitions. Fifth, pursuing strategic collaborations that combine diagnostic and therapeutic capabilities will strengthen biomarker-driven positioning and enable targeted indications. Sixth, adopting digital and decentralized clinical trial methodologies will broaden patient recruitment, accelerate data collection, and support post-approval evidence generation. Seventh, negotiating innovative contracting arrangements with payers, including outcome-based agreements, will align pricing with clinical performance and de-risk uptake for high-cost therapies. Finally, fostering cross-functional alignment between R&D, regulatory, manufacturing, and commercial teams will ensure faster decision cycles and coherent market entry strategies. Taken together, these recommendations provide a pragmatic roadmap for organizations seeking to sustain innovation while navigating cost pressures and access barriers.

Transparent multi-method research approach combining stakeholder interviews, literature synthesis, and data triangulation to validate oncology insights and assumptions

This research integrates primary and secondary methodologies designed to deliver rigorous, validated insights. Primary research incorporated structured interviews with a cross-section of stakeholders including clinical investigators, hospital pharmacists, payers, specialty clinic directors, and executives from biopharma and contract manufacturing organizations. These interviews were used to capture operational realities, procurement behaviors, and evidence expectations from multiple vantage points. Secondary research involved a systematic review of peer-reviewed literature, regulatory guidance documents, public filings, conference proceedings, and technical white papers to construct a comprehensive evidence base. Data triangulation techniques reconciled insights across sources, and findings were cross-validated through follow-up expert consultations to ensure consistency and to resolve divergent perspectives.

Segment mapping was applied to align therapeutic classes, administration routes, molecule types, indications, end users, and distribution channels with observed adoption patterns and operational constraints. Quality assurance steps included methodological peer review, source traceability, and sensitivity analysis to identify areas of higher uncertainty. Limitations of the approach are acknowledged: stakeholder interviews reflect current practices and perceptions that can evolve rapidly, and public documentation may lag behind fast-moving innovations. To manage these constraints, the study emphasizes transparent assumptions and specific evidence citations for key conclusions, and it recommends that users complement this work with targeted primary engagements tailored to their strategic questions. Ethical standards and confidentiality protocols governed all primary interactions, and proprietary information shared by participants was treated in accordance with agreed confidentiality provisions.

Conclusive synthesis emphasizing the convergence of innovation, operational readiness, and policy considerations that determine long-term oncology impact

The synthesis of scientific innovation, operational complexity, and policy dynamics presented here highlights that oncology stakeholders must be both agile and deliberate. Advancements in immunotherapy and targeted agents offer meaningful clinical promise, but realizing that promise at scale requires integrated strategies spanning manufacturing resilience, evidence generation, and adaptive commercialization. Tariff and trade developments through 2025 add a layer of operational risk that can affect input costs, procurement behavior, and access pathways, making supply chain visibility and scenario planning essential priorities.

Segmentation and regional analyses demonstrate that therapeutic, delivery, and geographic nuances demand tailored approaches rather than one-size-fits-all plans. Companies that invest in modular manufacturing, smart partnerships, and early payer engagement will be better positioned to navigate reimbursement complexity and to secure durable adoption for innovative treatments. Meanwhile, health systems and payers benefit from clearer outcome data and collaboration models that align cost with long-term patient benefit. In closing, the current environment rewards organizations that combine scientific rigor with operational foresight; stakeholders who integrate these dimensions into strategy development will be best placed to convert therapeutic breakthroughs into sustained clinical and commercial success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of personalized neoantigen vaccine platforms targeting tumor-specific mutations in solid cancers
  • 5.2. Growing integration of ultra-sensitive liquid biopsy assays for minimal residual disease monitoring in hematologic malignancies
  • 5.3. Expansion of CD19-targeted CAR T cell therapies into earlier lines of diffuse large B cell lymphoma treatment protocols
  • 5.4. Emergence of next generation KRAS G12C and G12D inhibitors demonstrating durable responses across lung and colorectal cancers
  • 5.5. Increasing partnerships between pharmaceutical companies and diagnostic developers for PD-L1 companion diagnostic co-development programs

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oncology Drugs Market, by Drug Class

  • 8.1. Chemotherapy Agents
    • 8.1.1. Alkylating Agents
    • 8.1.2. Antimetabolites
  • 8.2. Hormonal Therapy Agents
  • 8.3. Immunotherapy Agents
    • 8.3.1. CAR T-Cell Therapy
    • 8.3.2. Checkpoint Inhibitors
      • 8.3.2.1. CTLA-4 Inhibitors
      • 8.3.2.2. PD-1/PD-L1 Inhibitors
  • 8.4. Targeted Therapy Agents
    • 8.4.1. Monoclonal Antibodies
      • 8.4.1.1. Chimeric
      • 8.4.1.2. Humanized
    • 8.4.2. Small Molecule Inhibitors
      • 8.4.2.1. Cyclin-Dependent Kinase Inhibitors
      • 8.4.2.2. Tyrosine Kinase Inhibitors

9. Oncology Drugs Market, by Route of Administration

  • 9.1. Injectable
    • 9.1.1. Intramuscular
    • 9.1.2. Intravenous
    • 9.1.3. Subcutaneous
  • 9.2. Oral

10. Oncology Drugs Market, by Molecule Type

  • 10.1. Biologics
    • 10.1.1. Monoclonal Antibodies
    • 10.1.2. Vaccines
  • 10.2. Small Molecules

11. Oncology Drugs Market, by Indication

  • 11.1. Blood Cancer
    • 11.1.1. Leukemia
      • 11.1.1.1. Acute Myeloid Leukemia
      • 11.1.1.2. Chronic Lymphocytic Leukemia
    • 11.1.2. Lymphoma
      • 11.1.2.1. Hodgkin Lymphoma
      • 11.1.2.2. Non-Hodgkin Lymphoma
  • 11.2. Breast Cancer
  • 11.3. Colorectal Cancer
  • 11.4. Lung Cancer
  • 11.5. Prostate Cancer

12. Oncology Drugs Market, by End User

  • 12.1. Hospitals
  • 12.2. Research Institutes
  • 12.3. Specialty Clinics

13. Oncology Drugs Market, by Distribution Channel

  • 13.1. Hospital Pharmacies
  • 13.2. Online Pharmacies
  • 13.3. Retail Pharmacies

14. Oncology Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Oncology Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Oncology Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. AbbVie Inc.
    • 17.3.2. Agenus Inc.
    • 17.3.3. Amgen Inc.
    • 17.3.4. Apres-demain SA
    • 17.3.5. Aspen Pharmacare Holdings Limited
    • 17.3.6. Astellas Pharma Inc.
    • 17.3.7. AstraZeneca PLC
    • 17.3.8. Bayer AG
    • 17.3.9. BeiGene, Inc.
    • 17.3.10. Bristol-Myers Squibb Company
    • 17.3.11. C.H. Boehringer Sohn AG & Co. KG
    • 17.3.12. Cipla Limited
    • 17.3.13. Eli Lilly and Company
    • 17.3.14. GSK plc
    • 17.3.15. Johnson & Johnson Services, Inc.
    • 17.3.16. Merck KGaA
    • 17.3.17. Pfizer Inc.
    • 17.3.18. Puma Biotechnology, Inc.
    • 17.3.19. Roche Holding AG
    • 17.3.20. Shorla Oncology
    • 17.3.21. Sun Pharmaceutical Industries Ltd
    • 17.3.22. Sutro Biopharma, Inc.
    • 17.3.23. Takeda Pharmaceutical Company Limited
    • 17.3.24. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. ONCOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. ONCOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ONCOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PD-1/PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PD-1/PD-L1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PD-1/PD-L1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PD-1/PD-L1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PD-1/PD-L1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PD-1/PD-L1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHIMERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHIMERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHIMERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HUMANIZED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HUMANIZED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HUMANIZED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CYCLIN-DEPENDENT KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CYCLIN-DEPENDENT KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CYCLIN-DEPENDENT KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CYCLIN-DEPENDENT KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CYCLIN-DEPENDENT KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CYCLIN-DEPENDENT KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 301. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 302. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 303. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 304. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 305. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 306. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 307. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 308. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 309. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 310. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 311. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 312. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 313. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 316. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 317. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 318. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 319. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2024 (USD MILLION)
  • TABLE 320. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2025-2032 (USD MILLION)
  • TABLE 321. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 322. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 323. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 324. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)
  • TABLE 325. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 326. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 327. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 328. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 329. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 330. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 331. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)

TABLE 3